Quinupristin/dalfopristin: A novel selective spectrum antibiotic for the treatment of multi-resistant and other gram-positive pathogens

Clinical Microbiology Newsletter

Volumn 21, Issue 13, 1999, Pages 103-112

  Nadler, Harriette ^a   Dowzicky, Michael J ^a   Feger, Celine ^a   Pease, Michael R ^a   Prokocimer, Philippe ^a  

^a SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMPICILLIN; AZTREONAM; CEFOTAXIME; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; CIPROFLOXACIN; DALFOPRISTIN; DOXYCYCLINE; GENTAMICIN; QUINUPRISTIN; TETRACYCLINE;

ANTIBIOTIC THERAPY; BACTERICIDAL ACTIVITY; CLINICAL TRIAL; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG STRUCTURE; GRAM POSITIVE BACTERIUM; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; PH; PHASE 3 CLINICAL TRIAL; POSTANTIBIOTIC EFFECT; REVIEW;

EID: 0033168935     PISSN: 01964399     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0196-4399(00)80041-0     Document Type: Article

References (52)

1. Vannuffel, P. and C. Cocito. 1996. Mechanism of action of streptogramins and macrolides. Drugs. (suppl. 1):20-30.
2. Bouanchaud, D.H. 1992. In vitro and in vivo synergic activity and fractional inhibitory concentration (FIC) of the components of a semisynthetic streptogramin, RP 59500. J. Antimicrob. Chemother. 30(Suppl. A):95-99.
3. Gazagne, L. et al. 1998. In vitro activity of streptogramins against methicillin-resistant Staphylococcus aureus with decreased susceptibility to dalfopristin. 3.23, p. 37. In Abstracts of the 4th International Conference on the Macrolides, Azalides, Streptogramins and Ketolides. American Society for Microbiology, Washington D.C.
4. Thabaut, A. et al. 1999. Update on the in Vitro Activity of Quinupristin/Dalfopristin Against Bacterial Isolates from Hospitals in France. In press.
5. National Committee for Clinical Laboratory Standards: Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically. 1997. NCCLS document M7-A4, Villanova, PA.
6. National Committee for Clinical Laboratory Standards: Performance Standards for Antimicrobial Disk Susceptibility Tests. 1997. NCCLS document M2-A6, Villanova, PA.
7. National Committee for Clinical Laboratory Standards: Performance Standard for Antimicrobial Susceptibility Testing; Eighth Informational Supplement. 1998. NCCLS document M100-S8, Villanova, PA.
8. Dowzicky, M. et al. 1998. Evaluation of in vitro activity of quinupristin/dalfopristin and comparator antimicrobial agents against worldwide clinical trial and other laboratory isolates. Amer. J. Med. 104:34S-42S.
9. Synercid Product Monograph. 1999. Data on file at Rhône-Poulenc Rorer.
10. Tenover, F.C. et al. 1998. Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides. J. Clin. Microbiol. 36:1020-1027.
11. Ploy, M.C. et al. 1998. First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital. Lancet 351:1212.
12. Jones, R. et al. 1998. Antimicrobial activity of quinupristin-dalfopristin (RP 59500, synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada. Diag. Microbiol. Infect. Dis. 31:437-451.
13. Willey, B.M., A. McGeer, and D.E. Low. 1999. A Simple Approach to the Correct Species Identification of Enterococcus Faecium and Enterococcus Faecalis for Epidemiological and Quinupristin/Dalfopristin Treatment Purposes. In press.
14. 14C-RP57669:RP54476, 30:70) after a Single 60 Minute IV Infusion of 500 mg (50 μCi) to 6 Healthy Male Volunteers. Report SYN 111. Data on file at Rhône-Poulenc Rorer.
15. 14C-RP54476, 30:70) after a Single 60 Minute IV Infusion of 500 mg (50 μCi) to 6 Healthy Male Volunteers. Report SYN 112. Data on file at Rhône-Poulenc Rorer.
16. Barry A.L., P.C. Fuchs, and S.D. Brown. 1997. Provisional interpretative criteria for quinupristin/dalfopristin susceptibility tests. J. Antimicrob. Chemother. 39(Suppl. A):87-92.
17. Brumfitt, W., J.M. Hamilton-Miller, and S. Shah. 1992, In-vitro activity of RP 59500, a new semisynthetic streptogramin antibiotic, against gram-positive bacteria. J. Antimicrob. Chemother. 30(Suppl. A):29-37.
18. Fass, RJ. 1991. In vitro activity of RP 59500, a semisynthetic injectable pristinamycin, against staphylococci, streptococci, and enterococci. Antimicrob. Agents Chemother. 35:553-559.
19. Jones, R.N. 1996. Medium and supplement effects on the antimicrobial activity of quinupristin/dalfopristin tested by agar dilution and etest methods. Diag. Microbiol. Infect. Dis. 26:99-102.
20. Low, D.E. et al. 1998. The effect of changes in media, length of incubation and incubation environment on the determination of synercid® minimum inhibitory concentrations (MIC) for viridans streptococci. 3.01, p. 31. In Abstracts of the 4th International Conference on the Macrolides, Azalides, Streptogramins and Ketolides. American Society for Microbiology, Washington D.C.
21. Baltch, A.L., R.P. Smith, and W. Ritz. 1995. In Vitro Effect of RP 59500 (Quinupristin/dalfopristin) and Ampicillin (amp) on Vancomycin-resistant Enterococci (VRE), Singly and in Combination. Data on file at Rhône-Poulenc Rorer.
22. Bergeron, M. and G. Montay. 1997. The pharmacokinetics of quinupristin/dalfopristin in laboratory animals and in humans. J. Antimicrob. Chemother. 39(Suppl.A):129-138.
23. Fuchs, P., A. Barry, and S. Brown. 1998. Bactericidal Activity of Quinupristin/ Dalfopristin Against Selected Isolates of Staphylococcus Aureus. Data on file at Rhône-Poulenc Rorer.
24. Vouillamoz, J. et al. 1998. Synercid (SYN) alone or combined with cefepime (FEP) in the treatment (Rx) of experimental endocarditis (EE) due to methicillin-resistant Staphylococcus aureus (MRSA) resistant to macrolide-lincosamide-streptogramin B (MLSB- Resistant). B-76, p. 67. In Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington D.C.
25. Fantin, B. et al. 1997. Influence of inducible cross-resistance to macrolides, lincosamides, and streptogramin B-type antibiotics in Enterococcus faecium on activity of quinupristin-dalfopristin in vitro and in rabbits with experimental endocarditis. Antimicrob. Agents Chemother. 41:931-935.
26. Craig, W. and S. Ebert. 1993. Pharmacodynamic activities of RP 59500 in an animal infection model. 470, p. 205. In Abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington D.C.
27. Chin, N.X. and H.C. Neu. 1992. Post-antibiotic effect of the new streptogramin RP 59500. Eur. J. Clin. Microbiol. Infect. Dis. 11:642-645.
28. Boswell, F.J., J.M. Andrews, and R. Wise. 1994. The postantibiotic effect of RP 59500 on Staphylococcus aureus including strains with a raised MBC. J. Antimicrob. Chemother. 33:1219-1222.
29. Nougayrede, A., N. Berthaud, and D.H. Bouanchaud. 1992. Post-antibiotic effects of RP 59500 with Staphylococcus aureus. J. Antimicrob. Chemother. 30(Suppl.A):101-106.
30. Pankuch, G., M. Jacobs, and P. Appelbaum. 1998. Postantibiotic effect and postantibiotic sub-MIC effect of quinupristin-dalfopristin against gram-positive and -negative organisms. Antimicrob. Agents and Chemother. 42:3028-3031.
31. Vesga, O., D. Andes, and W.A. Craig. 1996. In Vivo Pharmacodynamic Activity of Synercid (RP 59500) Against Multiple Pathogens. Data on file at Rhône-Poulenc Rorer.
32. Fantin, B. et al. 1995. Critical influence of resistance of streptogramin B-type antibiotics on activity of RP 59500 (quinupristin-dalfopristin) in experimental endocarditis due to Staphylococcus aureus. Antimicrob. Agents Chemother. 39:400-405.
33. Craig, W. 1998. Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26:1-12.
34. BSAC standardized disc sensitivity testing method. 1998. Newslett. Brit. Soc. Antimicrob. Chemother.
35. Nadler, H. et al. 1998. Correlation of clinical data with MICs of selected targeted pathogens from worldwide quinupristin/dalfopristin (Q/D) clinical trials. 2.13, p. 30. In Abstracts of the 4th International Conference on the Macrolides, Azalides, Streptogramins and Ketolides. American Society for Microbiology, Washington D.C.
36. Tomasz, A. 1996. Frequency of Resistance to RP 59500, RP 57669, and Erythromycin. Letter to Harriette Nadler, dated Nov. 7, 1996. Data on file at Rhône-Poulenc Rorer.
37. Dutka-Malen, S., N. Berthaud, and J.F. Desnottes. 1996. RP 57669/RP 54476 (Rp 59500): Resistance Mutation Frequencies in Staphylococcus Aureus, Enterococcus Faecalis, Enterococcus Faecium, Haemophilus Influenzae and Streptococcus Pneumoniae. Report number 824. Data on file at Rhône-Poulenc Rorer.
38. Mulazimoglu, L., S.D. Drenning, and V.L. Yu. 1996. In vitro activities of two novel oxazolidinones (U100592 and U100766), a new fluoroquinolone (trovafloxacin), and dalfopristin-quinupristin against Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob. Agents Chemother. 40:2428-2430.
39. Fantin, B. et al. 1997. Influence of inducible cross-resistance to macrolides, lincosamides, and streptogramin B-type antibiotics in Enterococcus faecium on activity of quinupristin-dalfopristin in vitro and in rabbits with experimental endocarditis. Antimicrob. Agents Chemother. 41:931-935.
40. Fantin, B. 1998. Influence of Resistance to Streptogramin A-type Antibiotics on the Activity of Q:D in Vitro and in Experimental Endocarditis Due to Staphylococcus Aureus. Data on file at Rhône-Poulenc Rorer.
41. Nadler, H. et al. 1998. Characterization of isolates associated with emerging resistance to synercid (quinupristin/ dalfopristin; Q/D) during worldwide clinical program. 53, p. 84. In Abstracts of the Infectious Disease Society of America Meeting. American Society for Microbiology, Washington D.C.
42. Fish, D.N., S.C. Piscitielli, and L.H. Danziger. 1995. Development of resistance during antimicrobial therapy: A review of antibiotic classes and patient characteristics in 173 studies. Pharmacotherapy 15:279-291.
43. Leclercq R. et al. 1992. Activity of RP 59500, a new parental semisynthetic streptogramin, against staphylococci with various mechanisms of resistance to macrolide-lincosamide-streptogramin antibiotics. J. Antimicrob. Chemother. 30(Suppl A):67-75.
44. Pechere, J.C. 1996. Streptogramins: A unique class of antibiotics. Drugs (Suppl. 1):13-19.
45. El Solh, N. et al. 1993. Analysis of staphylococcal elements conferring resistance to streptogramin A (RP 54476). 217, p. 159. In Abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington D.C.
46. Watanakunakorn, C. 1976. Clindamycin therapy of Staphylococcus aureus endocarditis: Clinical relapse and development of resistance to clindamycin, lincomycin, and erythromycin. Amer. J. Med. 60:419-425.
47. Bozdogan, B. and R. Leclercq. 1997. Intrinsic and acquired resistance to dalfopristin (streptogramin A) in enterococcus spp. C-79, p. 59. In Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington D.C.
48. Fagon, J.-Y. et al. 1999. Treatment of gram positive nosocomial pneumonia: Prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Ann. Int. Med. In press.
49. Nichols, R. et al. 1999. Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: Two randomized, multicenter studies of quinupristin/dalfopristin (synercid) versus cefazolin, oxacillin or vancomycin. J. Antimicrob. Chemother. In press.
50. Moellering, R.C. et al. 1999. The efficacy and safety of quinupristin/ dalfopristin (synercid) for the treatment of infections caused by vancomycin- Resistant Enterococcus faecium. Lancet. In press.
51. Public Health Initiative Research Institute. 1997. Report from the bacterial antibiotic resistance group/infectious disease center. U.S. Government Printing Office.
52. Luna, V.A. et al. 1998. Transfer of the mefe gene from Streptococcus pneumoniae, Micrococcus luteus, and Coryne-bacterium jeikeium to other gram-positive bacteria. C-34, p. 78. In Abstracts of 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA. American Society for Microbiology, Washington D.C.